Study to Evaluate Safety and Immunogenicity of DNA Vaccine N-pVAX1 Against Crimean Congo Hemorrhagic Fever

Inclusion Criteria

• •1. Men and women between the ages of 18 and 60 years (at the time of consent).
• •2. Healthy participant, according to the investigator's clinical judgment, as established by medical history, vital signs, physical examination, and laboratory assessments.
• •3. No clinically significant laboratory abnormalities as determined by the investigator at screening.
• •Note: one retest of lab tests is allowed within the screening window.
• •4. Negative HIV 1/2 antibody/antigen test, hepatitis B surface antigen (HBsAg), and hepatitis C virus (HCV) antibody at screening.
• •5. Participant with a body mass index (BMI) 20-30.0 kg/m2.
• •6. Provide written informed consent before initiation of any study procedures.
• •7. A female participant is eligible for this study if she is one of the following:
• •* of non-childbearing potential (i.e., women who have had a hysterectomy or tubal ligation or are postmenopausal, as defined by no menses in greater than or equal to 1 year)
• •* of childbearing potential but agrees to practice highly effective contraception or abstinence (if this is the preferred and usual lifestyle of the participant) from 30 days prior to vaccination up to 3 months after last vaccination.
• •Highly effective methods of contraception include one or more of the following:
• •1. male partner who is sterile (vasectomised) prior to the female study subject's entry into the study and is the sole sexual partner for the female subject;
• •2. hormonal (oral, intravaginal, transdermal, implantable or injectable)
• •3. an intrauterine hormone-releasing system (IUS)
• •4. an intrauterine device (IUD) with a documented failure rate of \< 1%.
• •10. Able to understand and comply with planned study procedures and willing to be available for all study-required procedures, visits and calls for the duration of the study.